BRUKINSA在初治CLL患者中显示出强劲的6年PFS
These long-term efficacy data for BRUKINSA in treatment-naïve CLL patients are highly significant, establishing it as a durable and effective foundational therapy.
BRUKINSA demonstrated a 74% 6-year progression-free survival rate in treatment-naïve CLL patients.
BeOne医药公布了里程碑式的数据，显示BRUKINSA在初治慢性淋巴细胞白血病（CLL）患者中达到了74%的6年无进展生存率（PFS）。这些在ASH 2025上公布的结果，强调了BRUKINSA作为CLL基础治疗的长期疗效和持久性，巩固了其市场地位。
These long-term efficacy data for BRUKINSA in treatment-naïve CLL patients are highly significant, establishing it as a durable and effective foundational therapy. This reinforces its value proposition for healthcare providers and patients globally. In APAC, where CLL incidence is notable, these results will influence treatment guidelines and patient selection, potentially leading to wider adoption and improved outcomes.
The strong long-term efficacy of BRUKINSA in treatment-naïve CLL is crucial for APAC markets. CLL is a significant hematological malignancy in the region. These data will support market access, reimbursement discussions, and physician confidence, potentially leading to increased use of BRUKINSA as a first-line treatment for CLL patients across Asia-Pacific.
此信号在行业全局中的位置。
https://www.beigene.com/news/brukinsa-delivers-landmark-74-6-year-pfs-in-patients-with-treatment-na-ive-chronic-lymphocytic-leukemia
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录